Reports of Injuries, Deaths Prompt FDA to Recall Heart Failure Devices
WEDNESDAY, April 17, 2024 -- The HeartMate II and HeartMate 3, manufactured by Thoratec Corp., a subsidiary of Abbott Laboratories, are now under a strict U.S. Food and Drug Administration recall after being tied to 273 known injuries and 14... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 17, 2024 Category: Pharmaceuticals Source Type: news
One in THREE people will be struck down with 'silent killer' amid huge surge in condition
Danish scientists discovered that among those with the heart condition, up to two in five people are likely to develop heart failure over their lifetime. (Source: the Mail online | Health)
Source: the Mail online | Health - April 17, 2024 Category: Consumer Health News Source Type: news
Study: Heart failure, not stroke, most common complication of atrial fibrillation
Doctors tell patients with atrial fibrillation, which causes an irregular and often abnormally rapid heart rate, to beware of an increased risk of stroke. But the threat of heart failure should be even more worrisome. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 17, 2024 Category: Consumer Health News Source Type: news
FDA Recalls Heart Failure Devices Linked to Injuries and Deaths
WEDNESDAY, April 17, 2024 -- Two implanted heart devices used by patients in end-stage heart failure are now under a strict U.S. Food and Drug Administration recall, after being tied to 273 known injuries and 14 deaths, the agency said Tuesday.
The... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 17, 2024 Category: General Medicine Source Type: news
EMPACT-MI: Another SGLT2 Inhibitor Miss Post-MI EMPACT-MI: Another SGLT2 Inhibitor Miss Post-MI
Empagliflozin added to standard care did not improve outcomes in post-MI patients at risk for heart failure. John Mandrola, MD, sees the diminishing returns for add-on drugs as positive for patients.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 12, 2024 Category: Cardiology Tags: Cardiology Commentary Source Type: news
How to Talk to Your Family About Their Heart Health History
Hypertrophic obstructive cardiomyopathy (HOCM) is the most common genetic heart disease, affecting about 1 in every 500 people, according to the American Heart Association (AHA). In people with HOCM, genetic variants cause the heart’s walls to thicken and stiffen, blocking blood from flowing freely from the left ventricle to the aorta. This, in turn, results in shortness of breath and chest pain (especially during physical activity), abnormal heart rhythms, lightheadedness, dizziness, and fainting, and can worsen over time.
[time-brightcove not-tgx=”true”]
If a parent has HOCM, offspring have a 50% ch...
Source: TIME: Health - April 11, 2024 Category: Consumer Health News Authors: Sarah Klein Tags: Uncategorized Evergreen freelance healthscienceclimate Source Type: news
ACC: Empagliflozin Does Not Cut Risk for Heart Failure After Acute MI
WEDNESDAY, April 10, 2024 -- Empagliflozin does not reduce the risk for first hospitalization for heart failure or death among patients at increased risk for heart failure after acute myocardial infarction, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 10, 2024 Category: Pharmaceuticals Source Type: news
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 …
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE…#primaryresults #incorporatedcytk #sequoiahcm #efficacy #phase3 #hcm #heartfailure #lisbon #portugal #martinmaron (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2024 Category: Consumer Health News Source Type: news
Beta Blocker Meds May Not Help Some Heart Attack Survivors
WEDNESDAY, April 10, 2024 -- Beta blockers appear to be useless when prescribed to heart attack survivors who aren ' t suffering from heart failure, a new clinical trial indicates.
The study calls into question the routine of prescribing beta... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 10, 2024 Category: General Medicine Source Type: news
ACC: Ventura Shunt Does Not Improve Primary End Point in Heart Failure
TUESDAY, April 9, 2024– For patients with heart failure, transcatheter placement of a Ventura interarterial shunt does not improve the primary end point, according to a study presented at the annual meeting of the American College of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 9, 2024 Category: Pharmaceuticals Source Type: news
ACC: Semaglutide Beneficial in Obesity-Related Heart Failure, Type 2 Diabetes
TUESDAY, April 9, 2024 -- Semaglutide leads to larger reductions in heart failure-related symptoms and physical limitations among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 9, 2024 Category: Pharmaceuticals Source Type: news
Wegovy Helps Those With Both Diabetes, Heart Failure: Study
TUESDAY, April 9, 2024 -- For people struggling with both diabetes and a common type of heart failure, the weight-loss drug Wegovy may do more for their health than help them shed pounds, new research suggests.
In the study, published Saturday in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 9, 2024 Category: General Medicine Source Type: news
Suffering Shouldn ’ t Be a Normal Part of Womanhood
One of the most important lessons medical schools teach is one my mom mastered as a teenager left to fill her own mother’s shoes: how to figure out who is really sick and needs immediate attention and who can wait (or what we in the medical field call “triage”). Nothing I learned in med school or since has contradicted what I learned at Bertha’s knee.
At the time, the practice of medicine was rudimentary—and that’s putting it nicely. So, the diagnoses typically made at home were probably not that different from those of a bona fide doctor. The more serious common ailments were things ...
Source: TIME: Health - April 9, 2024 Category: Consumer Health News Authors: Dr. Sharon Malone Tags: Uncategorized health Source Type: news
ACC: Empagliflozin Cuts Heart Failure Hospitalization Risk After AMI
MONDAY, April 8, 2024 -- For patients with acute myocardial infarction at risk for heart failure, empagliflozin reduces the risk for heart failure hospitalization, according to a study published online April 6 in Circulation to coincide with the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 8, 2024 Category: Pharmaceuticals Source Type: news
Wegovy Helps HFpEF Patients With Diabetes Mellitus
(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 7, 2024 Category: Cardiology Source Type: news
